Is ITGR a good stock to buy right now?

Based on our 6-factor quantitative model, Integer Holdings Corp (ITGR) receives a "Hold" rating with a composite score of 42.5/100. It is ranked #1,309 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 60/100, Momentum 33/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for ITGR?

Integer Holdings Corp (ITGR) has a "Hold" rating and 3-star score. The composite score of 42.5 ranks it #1,309 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is ITGR in?

Integer Holdings Corp operates in the Healthcare sector (Medical Equipment industry) with a market cap of $2.97 billion. It is classified as a mid-cap stock.

Does ITGR pay a dividend?

ITGR does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is ITGR's P/E ratio?

ITGR has a trailing P/E ratio of 32.35x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is ITGR?

ITGR's quality factor score is 50/100. Gross margin: 27.2%. ROE: 5.1% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is ITGR valued compared to peers?

ITGR's value factor score is 60/100 (higher = cheaper). Key multiples: P/E 32.4x, EV/EBITDA 18.3x. The stock appears attractively valued versus peers.

What is ITGR's debt level?

ITGR's debt-to-equity ratio is 68%. Sector average: 32%. Moderate leverage is normal for established companies.

ITGR has a beta of 0.72, meaning it is less volatile than the market. Stability score: 62/100.

Does ITGR have high short interest?

ITGR's short interest factor score is 12/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

ITGR Stock Analysis: Top Mid-Cap Hold (Score 42.5/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
ITGR	-1.80%	-2.00%	+2.20%	+8.52%	-25.23%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.73%	-5.61%	+1.86%	+8.88%	-54.76%	-	-	-
Alpha vs Sector	-0.45%	-2.34%	+6.01%	+13.36%	-34.44%	-	-	-

Metric	ITGR	Benchmark
P/E Ratio	32.4x	+37%
EV/EBITDA	18.3x	+188%
Price / Book	1.7x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
ITGR Integer Holdings Corp	43	50	60	33	32.4x	5.1%	27.2%	4.8%	7.2%	68.0x	$3.0B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Operating Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%	0.1%
Net Margin %	0.0%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	-0.1%	0.1%	0.1%	0.0%
FCF Margin %	-12.6%	-	-	-	-	-	12.5%	9.3%	10.1%	7.0%	3.4%
ROE %	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	-0.1%	0.2%	0.1%	0.0%
ROA %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-0.0%	0.1%	0.0%	0.0%
ROIC %	0.1%	6.0%	6.3%	5.3%	4.1%	4.9%	4.9%	6.4%	6.3%	4.5%	3.6%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.3%

Operating Margin %

0.1%

EBITDA Margin %

0.1%

0.2%

0.1%

Net Margin %

0.0%

0.1%

0.0%

0.1%

-0.1%

0.1%

0.0%

FCF Margin %

-12.6%

12.5%

9.3%

10.1%

7.0%

3.4%

ROE %

0.1%

0.0%

0.1%

-0.1%

0.2%

0.1%

0.0%

ROA %

0.0%

-0.0%

0.1%

0.0%

ROIC %

0.1%

6.0%

6.3%

5.3%

4.1%

4.9%

6.4%

6.3%

4.5%

3.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
	$1.8B	$1.9B	$1.7B	$1.6B	$1.4B	$1.2B	$1.1B	$1.3B	$1.2B	$1.5B	$1.4B
	—	$1.4B	$1.3B	$1.2B	$1.0B	$884M	—	—	—	—	—
	$492M	$500M	$459M	$418M	$359M	$337M	$286M	$355M	$363M	$394M	$378M
Gross Margin	27.2%	27.0%	26.7%	26.2%	26.1%	27.6%	26.6%	28.2%	29.8%	31.2%	31.4%
	—	$212M	$185M	$176M	$161M	$141M	—	—	—	—	—
Research & Development	—	—	—	—	—	—	$48M	$47M	$49M	$55M	$55M
Depreciation	—	—	—	—	—	—	$84M	$93M	$138M	$114M	$98M
Total Operating Expenses	—	$279M	$251M	$251M	$238M	$201M	—	—	—	—	—
	$223M	$221M	$208M	$167M	$121M	$136M	$121M	$158M	$156M	$139M	$108M
EBIT	$223M	$221M	$208M	$167M	$121M	$136M	$121M	$158M	$156M	$139M	$108M
EBITDA	$223M	$221M	$208M	$167M	$121M	$136M	$203M	$243M	$293M	$229M	$194M
Operating Margin	12.3%	11.9%	12.1%	10.5%	8.8%	11.1%	11.2%	12.5%	12.8%	11.1%	8.6%
EBITDA Margin	12.3%	11.9%	12.1%	10.5%	8.8%	11.1%	18.9%	19.3%	24.1%	15.6%	14.0%
	—	—	—	$53M	$39M	$32M	$38M	$53M	$99M	$106M	$111M
	—	$125M	$148M	$107M	$76M	$101M	—	—	—	—	—
Income Tax Expense	—	$23M	$27M	$17M	$11M	$8M	$9M	$14M	$14M	-$45M	-$5M
	$90M	$103M	$120M	$91M	$66M	$97M	$77M	-$96M	$168M	$67M	$6M
Net Margin	4.8%	5.5%	7.0%	5.7%	4.8%	7.9%	7.2%	-7.6%	13.8%	5.9%	0.5%
	$2.96	$2.96	$3.57	$2.72	$2.00	$2.93	$2.35	$2.95	$5.23	$2.12	$0.19
Diluted EPS	$2.96	$2.89	$3.36	$2.69	$1.99	$2.91	$2.35	$2.95	$5.23	$2.12	$0.19
Weighted Avg Basic	—	35M	34M	33M	33M	33M	—	—	—	—	—
Weighted Avg Diluted	—	36M	36M	34M	33M	33M	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

$1.8B

$1.9B

$1.7B

$1.6B

$1.4B

$1.2B

$1.1B

$1.3B

$1.2B

$1.5B

$1.4B

—

$1.4B

$1.3B

$1.2B

$1.0B

$884M

—

$492M

$500M

$459M

$418M

$359M

$337M

$286M

$355M

$363M

$394M

$378M

Gross Margin

27.2%

27.0%

26.7%

26.2%

26.1%

27.6%

26.6%

28.2%

29.8%

31.2%

31.4%

—

$212M

$185M

$176M

$161M

$141M

—

Research & Development

—

$48M

$47M

$49M

$55M

Depreciation

—

$84M

$93M

$138M

$114M

$98M

Total Operating Expenses

—

$279M

$251M

$238M

$201M

—

$223M

$221M

$208M

$167M

$121M

$136M

$121M

$158M

$156M

$139M

$108M

EBIT

$223M

$221M

$208M

$167M

$121M

$136M

$121M

$158M

$156M

$139M

$108M

EBITDA

$223M

$221M

$208M

$167M

$121M

$136M

$203M

$243M

$293M

$229M

$194M

Operating Margin

12.3%

11.9%

12.1%

10.5%

8.8%

11.1%

11.2%

12.5%

12.8%

11.1%

8.6%

EBITDA Margin

12.3%

11.9%

12.1%

10.5%

8.8%

11.1%

18.9%

19.3%

24.1%

15.6%

14.0%

—

$53M

$39M

$32M

$38M

$53M

$99M

$106M

$111M

—

$125M

$148M

$107M

$76M

$101M

—

Income Tax Expense

—

$23M

$27M

$17M

$11M

$8M

$9M

$14M

-$45M

-$5M

$90M

$103M

$120M

$91M

$66M

$97M

$77M

-$96M

$168M

$67M

$6M

Net Margin

4.8%

5.5%

7.0%

5.7%

4.8%

7.9%

7.2%

-7.6%

13.8%

5.9%

0.5%

$2.96

$3.57

$2.72

$2.00

$2.93

$2.35

$2.95

$5.23

$2.12

$0.19

Diluted EPS

$2.96

$2.89

$3.36

$2.69

$1.99

$2.91

$2.35

$2.95

$5.23

$2.12

$0.19

Weighted Avg Basic

—

35M

34M

33M

—

Weighted Avg Diluted

—

36M

34M

33M

—

Integer Holdings Corp (ITGR) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Integer Holdings Corp Do?

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas. Integer Holdings Corp (ITGR) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Joseph W. Dziedzic and employs approximately 10,000 people, headquartered in Frisco, Texas. With a market capitalization of $3.0B, ITGR is one of the notable companies in the Healthcare sector.

Integer Holdings Corp (ITGR) Stock Rating — Hold (April 2026)

As of April 2026, Integer Holdings Corp receives a Hold rating with a composite score of 42.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ITGR ranks #1,309 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Integer Holdings Corp ranks #101 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ITGR Stock Price and 52-Week Range

Integer Holdings Corp (ITGR) currently trades at $85.11. The stock lost $1.56 (1.8%) in the most recent trading session. The 52-week high for ITGR is $127.56, which means the stock is currently trading -33.3% from its annual peak. The 52-week low is $62.00, putting the stock 37.3% above its annual trough. Recent trading volume was 286K shares, suggesting relatively thin trading activity.

Is ITGR Overvalued or Undervalued? — Valuation Analysis

Integer Holdings Corp (ITGR) carries a value factor score of 60/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 32.35x, compared to the Healthcare sector average of 23.63x — a premium of 37%. The price-to-book ratio stands at 1.66x, versus the sector average of 2.75x. The price-to-sales ratio is 1.60x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ITGR trades at 18.29x EV/EBITDA, versus 6.34x for the sector.

Overall, ITGR's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Integer Holdings Corp Profitability — ROE, Margins, and Quality Score

Integer Holdings Corp (ITGR) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 5.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 2.6% versus the sector average of -33.1%.

On a margin basis, Integer Holdings Corp reports gross margins of 27.2%, compared to 71.5% for the sector. The operating margin is 12.3% (sector: -66.1%). Net profit margin stands at 4.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 7.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

ITGR Debt, Balance Sheet, and Financial Health

Integer Holdings Corp has a debt-to-equity ratio of 68.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $1.19B. Cash and equivalents stand at $59M.

ITGR has a beta of 0.72, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Integer Holdings Corp is 62/100, reflecting average volatility within the normal range for its sector.

Integer Holdings Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Integer Holdings Corp reported revenue of $1.81B and earnings per share (EPS) of $2.96. Net income for the quarter was $90M. Gross margin was 27.2%. Operating income came in at $223M.

In FY 2025, Integer Holdings Corp reported revenue of $1.85B and earnings per share (EPS) of $2.96. Net income for the quarter was $103M. Gross margin was 27.0%. Revenue grew 8.0% year-over-year compared to FY 2024. Operating income came in at $221M.

In Q3 2025, Integer Holdings Corp reported revenue of $468M and earnings per share (EPS) of $1.13. Net income for the quarter was $40M. Gross margin was 27.0%. Revenue grew 8.4% year-over-year compared to Q3 2024. Operating income came in at $56M.

In Q2 2025, Integer Holdings Corp reported revenue of $476M and earnings per share (EPS) of $1.06. Net income for the quarter was $37M. Gross margin was 27.1%. Revenue grew 9.2% year-over-year compared to Q2 2024. Operating income came in at $59M.

Over the past 8 quarters, Integer Holdings Corp has demonstrated a growth trajectory, with revenue expanding from $436M to $1.81B. Investors analyzing ITGR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ITGR Dividend Yield and Income Analysis

Integer Holdings Corp (ITGR) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ITGR Momentum and Technical Analysis Profile

Integer Holdings Corp (ITGR) has a momentum factor score of 33/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 12/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ITGR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Integer Holdings Corp (ITGR) ranks #101 out of 838 stocks based on the Blank Capital composite score. This places ITGR in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ITGR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ITGR vs S&P 500 (SPY) comparison to assess how Integer Holdings Corp stacks up against the broader market across all factor dimensions.

ITGR Next Earnings Date

No upcoming earnings date has been announced for Integer Holdings Corp (ITGR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ITGR? — Investment Thesis Summary

Integer Holdings Corp presents a balanced picture with arguments on both sides. The value score of 60/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 33/100, a headwind for near-term performance. Low volatility (stability score 62/100) reduces downside risk.

In summary, Integer Holdings Corp (ITGR) earns a Hold rating with a composite score of 42.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ITGR stock.

Related Resources for ITGR Investors

Explore more research and tools: ITGR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ITGR head-to-head with peers: ITGR vs AZN, ITGR vs SLGL, ITGR vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Integer (ITGR) is a Top-Ranked Momentum Stock: Should You Buy?

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

Integer Holdings Corp (ITGR) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does Integer Holdings Corp Do?

Integer Holdings Corp (ITGR) Stock Rating — Hold (April 2026)

ITGR Stock Price and 52-Week Range

Is ITGR Overvalued or Undervalued? — Valuation Analysis

Integer Holdings Corp Profitability — ROE, Margins, and Quality Score

ITGR Debt, Balance Sheet, and Financial Health

Integer Holdings Corp Revenue and Earnings History — Quarterly Trend

ITGR Dividend Yield and Income Analysis

ITGR Momentum and Technical Analysis Profile

ITGR vs Competitors — Healthcare Sector Ranking and Peer Comparison

ITGR Next Earnings Date

Should You Buy ITGR? — Investment Thesis Summary

Related Resources for ITGR Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Integer (ITGR) is a Top-Ranked Momentum Stock: Should You Buy?

Why Integer (ITGR) is a Top Value Stock for the Long-Term

How The Integer Holdings (ITGR) Narrative Is Shifting As Analysts Revisit Recovery Expectations

Is Integer Holdings (ITGR) Offering Value After Mixed Long Term Share Price Performance

Integer Announces Conference Call to Discuss First Quarter 2026 Results